This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howe, R. A.
Right arrow Articles by MacGowan, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howe, R. A.
Right arrow Articles by MacGowan, A. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3651-3652, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3651-3652.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid

Robin A. Howe,1,2* Mandy Wootton,1,2 Alan R. Noel,1 Karen E. Bowker,1 Timothy R. Walsh,2 and Alasdair P. MacGowan1,2

Bristol Centre for Antimicrobial Research and Evaluation, Department of Medical Microbiology, Southmead Hospital, Bristol BS10 5NB,1 Bristol Centre for Antimicrobial Research and Evaluation, Department of Pathology and Microbiology, School of Medical Sciences, Clifton, Bristol, BS8 1TD, United Kingdom2

Received 26 December 2002/ Returned for modification 17 May 2003/ Accepted 23 July 2003

The susceptibilities of clinical vancomycin-intermediate Staphylococcus aureus (VISA), heterogenous VISA, and laboratory-generated linezolid-resistant S. aureus strains to the new oxazolidinone AZD2563 were assessed by agar dilution MIC determination. All clinical strains were susceptible to linezolid, and the linezolid MICs for them were equal to or twofold higher than those of AZD2563. Cross-resistance with linezolid was seen in laboratory-generated mutants, and for these strains the MIC of AZD2563 was twofold higher than that of linezolid.

* Corresponding author. Mailing address: Bristol Centre for Antimicrobial Research and Evaluation, Department of Medical Microbiology, Southmead Hospital, Bristol BS10 5NB, United Kingdom. Phone: 44 (0)117 959 6358. Fax: 44 (0)117 959 3154. E-mail: robin.howe{at}north-bristol.swest.nhs.uk.

Antimicrobial Agents and Chemotherapy, November 2003, p. 3651-3652, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3651-3652.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»